Since centrosome amplification is frequently observed in tumour biopsies from cancer patients4, it will be interesting to examine whether patients with tumours containing centrosome amplification respond better to BBI-608 and other Stat3 inhibitors in clinical trials. The gene discussed is STAT3; the disease is neoplasm.